Search Result

Results for "

320367-13-3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) GCGR (3) Isotope-Labeled Compounds (1) JNK (2) MEK (2) MMP (2)
By Research Areas:	Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Targets Recommended: CX3CR1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0119

Lixisenatide 2 Publications Verification	GCGR MEK Akt MMP JNK	Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^−/− Irs ^2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GCGR	Metabolic Disease
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GCGR MEK Akt MMP JNK	Neurological Disease
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Cat. No.	Product Name	Target	Research Area

HY-P0119

Lixisenatide 2 Publications Verification	GCGR MEK Akt MMP JNK	Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^−/− Irs ^2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GCGR	Metabolic Disease
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GCGR MEK Akt MMP JNK	Neurological Disease
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Cat. No.	Product Name	Chemical Structure

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA
Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ^?/? Irs ^2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.